FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081204780> ?p ?o ?g. }

• W3081204780 endingPage "2811" @default.
• W3081204780 startingPage "2811" @default.
• W3081204780 abstract "Abstract Background: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with generally poor outcome. Hallmark of MCL is the t(11;14)(q13;q32) chromosomal translocation resulting in overexpression of Cyclin D1 and consequently aberrant activity of CDK4. New molecular targeted drugs such as Palbociclib, an inhibitor of CDK4/6 or Bortezomib, a proteasome inhibitor, have shown promising results in preclinical studies and MCL patients. Our previous research revealed stabilization of the short-lived pro-apoptotic BH3-only protein NOXA as a critical determinant for sensitivity to Bortezomib and other inhibitors of the ubiquitin proteasome system (UPS). We here investigated the role of Cyclin D1-driven abnormal CDK4 activity for NOXA stabilization and induction of cell death upon treatment with UPS inhibitors and identified promising combinations utilizing Cyclin D1-driven CDK4 activity for effective therapy. Methods: Experiments were conducted in 4 MCL cell lines (JEKO-1, MINO, Rec1, and JVM-2) as well as in primary cells obtained from peripheral blood samples of MCL patients diagnosed according to the WHO criteria. Bortezomib resistant JEKO-BR cells were obtained by continuous treatment with increasing concentrations of Bortezomib. JEKO-BR gained a cross-resistance to Carfilzomib. Cell death was assessed by flow cytometry staining with AnnexinV-FITC and propidium iodide. Synergy was calculated using CompuSyn Software based on the Chou & Talalay's method. RNA and protein levels were quantified by q-PCR and immunoblotting, respectively. Results: Both pharmacological inhibition of CDK4 by Palbociclib and genetic knockdown of CDK4 or Cyclin D1 partially prevented proteasome inhibitor-mediated cell death as well as NOXA accumulation comparable to that observed upon siRNA-mediated NOXA depletion. Inhibition of CDK4 had only minor impact on NOXA (PMAIP1) mRNA expression but significantly reduced proteasome inhibitor-mediated stabilization of NOXA protein, mainly driven by an autophagy mediated proteolysis. In contrast, compounds interfering with NOXA ubiquitination, such as the fatty acid synthase (FASN) inhibitors Orlistat and Cerulenin or the neddylation inhibitor MLN4924, further enhanced NOXA stability upon treatment with the proteasome inhibitors Bortezomib or Carfilzomib leading to super-induction of NOXA protein. This was reflected by a highly synergistic ability to induce apoptosis in MCL cell lines and patient samples (n=11) but had only minor effect on lymphocytes or fibroblasts from normal donors (n=3). Again, induction of cell death as well as NOXA stabilization upon combination of Orlistat together with Bortezomib was antagonized by Palbociclib or by siRNA-driven knockdown of Cyclin D1, CDK4 or NOXA. Finally, to determine if FASN and/or neddylation inhibitors together with proteasome inhibitors may overcome Bortezomib resistance we tested different combinations and found that combining of the 3 compounds Bortezomib, Orlistat and MLN4924 was able to potently kill Bortezomib/Carfilzomib resistant MCL cells. Importantly, this combinatory treatment was still selective and had only minor effects on viability of normal lymphocytes. Conclusion: Our data demonstrate that the Cyclin D1-driven CDK4 activity in MCL is important for NOXA stabilization and induction of cell death upon treatment with UPS inhibitors. Importantly, this elevated CDK4 activity also opens the way for effective combination treatment of MCL using ubiquitin modulators together with proteasome inhibitors via super-induction of NOXA protein. On the other hand,particular caution is recommended when combining CDK4 inhibitors together with proteasome inhibitors. Disclosures No relevant conflicts of interest to declare." @default.
• W3081204780 created "2020-09-01" @default.
• W3081204780 creator A5000783269 @default.
• W3081204780 creator A5007551486 @default.
• W3081204780 creator A5011143893 @default.
• W3081204780 creator A5030901905 @default.
• W3081204780 creator A5035984667 @default.
• W3081204780 creator A5047674033 @default.
• W3081204780 creator A5075157221 @default.
• W3081204780 creator A5084729483 @default.
• W3081204780 creator A5088431290 @default.
• W3081204780 date "2017-12-07" @default.
• W3081204780 modified "2023-10-08" @default.
• W3081204780 title "Cyclin D1 Driven CDK4 Activity Is Responsible for Hypersensitivity to NOXA Inducing Combination Treatment in Mantle Cell Lymphoma (MCL) Cells" @default.
• W3081204780 doi "https://doi.org/10.1182/blood.v130.suppl_1.2811.2811" @default.
• W3081204780 hasPublicationYear "2017" @default.
• W3081204780 type Work @default.
• W3081204780 sameAs 3081204780 @default.
• W3081204780 citedByCount "0" @default.
• W3081204780 crossrefType "journal-article" @default.
• W3081204780 hasAuthorship W3081204780A5000783269 @default.
• W3081204780 hasAuthorship W3081204780A5007551486 @default.
• W3081204780 hasAuthorship W3081204780A5011143893 @default.
• W3081204780 hasAuthorship W3081204780A5030901905 @default.
• W3081204780 hasAuthorship W3081204780A5035984667 @default.
• W3081204780 hasAuthorship W3081204780A5047674033 @default.
• W3081204780 hasAuthorship W3081204780A5075157221 @default.
• W3081204780 hasAuthorship W3081204780A5084729483 @default.
• W3081204780 hasAuthorship W3081204780A5088431290 @default.
• W3081204780 hasConcept C185592680 @default.
• W3081204780 hasConcept C190283241 @default.
• W3081204780 hasConcept C199835354 @default.
• W3081204780 hasConcept C203014093 @default.
• W3081204780 hasConcept C27740335 @default.
• W3081204780 hasConcept C2775934118 @default.
• W3081204780 hasConcept C2776364478 @default.
• W3081204780 hasConcept C2777478702 @default.
• W3081204780 hasConcept C2777525834 @default.
• W3081204780 hasConcept C2778367456 @default.
• W3081204780 hasConcept C2779338263 @default.
• W3081204780 hasConcept C2780108899 @default.
• W3081204780 hasConcept C29537977 @default.
• W3081204780 hasConcept C31573885 @default.
• W3081204780 hasConcept C502942594 @default.
• W3081204780 hasConcept C55493867 @default.
• W3081204780 hasConcept C86803240 @default.
• W3081204780 hasConcept C95444343 @default.
• W3081204780 hasConceptScore W3081204780C185592680 @default.
• W3081204780 hasConceptScore W3081204780C190283241 @default.
• W3081204780 hasConceptScore W3081204780C199835354 @default.
• W3081204780 hasConceptScore W3081204780C203014093 @default.
• W3081204780 hasConceptScore W3081204780C27740335 @default.
• W3081204780 hasConceptScore W3081204780C2775934118 @default.
• W3081204780 hasConceptScore W3081204780C2776364478 @default.
• W3081204780 hasConceptScore W3081204780C2777478702 @default.
• W3081204780 hasConceptScore W3081204780C2777525834 @default.
• W3081204780 hasConceptScore W3081204780C2778367456 @default.
• W3081204780 hasConceptScore W3081204780C2779338263 @default.
• W3081204780 hasConceptScore W3081204780C2780108899 @default.
• W3081204780 hasConceptScore W3081204780C29537977 @default.
• W3081204780 hasConceptScore W3081204780C31573885 @default.
• W3081204780 hasConceptScore W3081204780C502942594 @default.
• W3081204780 hasConceptScore W3081204780C55493867 @default.
• W3081204780 hasConceptScore W3081204780C86803240 @default.
• W3081204780 hasConceptScore W3081204780C95444343 @default.
• W3081204780 hasLocation W30812047801 @default.
• W3081204780 hasOpenAccess W3081204780 @default.
• W3081204780 hasPrimaryLocation W30812047801 @default.
• W3081204780 hasRelatedWork W1965254621 @default.
• W3081204780 hasRelatedWork W2014014305 @default.
• W3081204780 hasRelatedWork W2038260677 @default.
• W3081204780 hasRelatedWork W2070662586 @default.
• W3081204780 hasRelatedWork W2108215179 @default.
• W3081204780 hasRelatedWork W2154423235 @default.
• W3081204780 hasRelatedWork W2551147408 @default.
• W3081204780 hasRelatedWork W2569412161 @default.
• W3081204780 hasRelatedWork W2582578468 @default.
• W3081204780 hasRelatedWork W2584724108 @default.
• W3081204780 hasRelatedWork W2585136534 @default.
• W3081204780 hasRelatedWork W2585926313 @default.
• W3081204780 hasRelatedWork W2766917114 @default.
• W3081204780 hasRelatedWork W2900113415 @default.
• W3081204780 hasRelatedWork W2977933905 @default.
• W3081204780 hasRelatedWork W2979341403 @default.
• W3081204780 hasRelatedWork W2979686470 @default.
• W3081204780 hasRelatedWork W2980802867 @default.
• W3081204780 hasRelatedWork W2996234821 @default.
• W3081204780 hasRelatedWork W922747079 @default.
• W3081204780 hasVolume "130" @default.
• W3081204780 isParatext "false" @default.
• W3081204780 isRetracted "false" @default.
• W3081204780 magId "3081204780" @default.
• W3081204780 workType "article" @default.